Abstract
Compounds with different sets of three of the four functional groups of (1R,2R,6S)-3-methyl-6-(prop-1-en-2- yl)cyclohex-3-ene-1,2-diol 1 possessing high antiparkinsonian activity were synthesized. The synthesized compounds were tested for the antiparkinsonian activity in vivo on a mouse model with MPTP neurotoxin. A pronounced antiparkinsonian effect of 1 can only be achieved if it contains all the four functional groups (two hydroxy groups and two double bonds). The 2-hydroxy group or the 3,4-double bond is not required for stimulating the exploratory activity of the animals.
Keywords: Antiparkinsonian activity, functional groups, (1R, 2R, 6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1, 2-diol, mice, MPTP model.
Medicinal Chemistry
Title:3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity
Volume: 9 Issue: 5
Author(s): Oleg V. Ardashov, Alla V. Pavlova, Dina V. Korchagina, Konstantin P. Volcho, Tat’ yana G. Tolstikova and Nariman F. Salakhutdinov
Affiliation:
Keywords: Antiparkinsonian activity, functional groups, (1R, 2R, 6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1, 2-diol, mice, MPTP model.
Abstract: Compounds with different sets of three of the four functional groups of (1R,2R,6S)-3-methyl-6-(prop-1-en-2- yl)cyclohex-3-ene-1,2-diol 1 possessing high antiparkinsonian activity were synthesized. The synthesized compounds were tested for the antiparkinsonian activity in vivo on a mouse model with MPTP neurotoxin. A pronounced antiparkinsonian effect of 1 can only be achieved if it contains all the four functional groups (two hydroxy groups and two double bonds). The 2-hydroxy group or the 3,4-double bond is not required for stimulating the exploratory activity of the animals.
Export Options
About this article
Cite this article as:
Ardashov V. Oleg, Pavlova V. Alla, Korchagina V. Dina, Volcho P. Konstantin, Tolstikova G. Tat’ yana and Salakhutdinov F. Nariman, 3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity, Medicinal Chemistry 2013; 9 (5) . https://dx.doi.org/10.2174/1573406411309050013
DOI https://dx.doi.org/10.2174/1573406411309050013 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Central Nervous System Agents in Medicinal Chemistry Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis
Current Topics in Medicinal Chemistry Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia
Current Neuropharmacology The Paradox of Caffeine-Zolpidem Interaction: A Network Analysis
Current Drug Targets Dopamine Receptor Interacting Proteins: Targeting Neuronal Calcium Sensor-1/D2 Dopamine Receptor Interaction for Antipsychotic Drug Development
Current Drug Targets Liquid Chromatography-Mass Spectrometry Method for the Determination of Olanzapine in Human Plasma and Application to a Bioequivalence Study
Current Pharmaceutical Analysis Calpain as a Potential Therapeutic Target in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets [General Articles] Cannabinoids: Mechanisms and Therapeutic Applications in the CNS
Current Medicinal Chemistry An Update on Human Stem Cell-Based Therapy in Parkinson's Disease
Current Stem Cell Research & Therapy Autism Spectrum Disorders: Etiology and Pharmacotherapy
Current Drug Therapy Is a "Mitochondrial Psychiatry" in the Future? A Review
Current Psychiatry Reviews The GABA Shunt: An Attractive and Potential Therapeutic Target in the Treatment of Epileptic Disorders
Current Drug Metabolism Involvement of the Endocannabinoid System in Motor Disorders
Current Medicinal Chemistry - Central Nervous System Agents Enhanced α-Synuclein Expression in Human Neurodegenerative Diseases: Pathogenetic and Therapeutic Implications
Current Protein & Peptide Science The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinsons Disease
Current Clinical Pharmacology Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?
CNS & Neurological Disorders - Drug Targets